Dosing & Uses
Dosage Forms & Strengths
topical foam (Enstilar)
Suspension (scalp and body): Apply to affected area(s) qDay for up to 8 weeks; may discontinue treatment earlier, if cleared; not to exceed 100 g/week
Ointment: Apply topical layer of ointment to affected area(s) qDay for up to 4 weeks; do not exceed 100 g/week
Foam: Apply topically to affected area(s) qDay for up to 4 weeks
Dosage Forms & Strengths
Indicated for plaque psoriasis of the scalp
<12 years: Safety and efficacy not established
Suspension (12-17 years): Apply to affected area(s) qDay for up to 8 weeks; may discontinue treatment earlier, if cleared; do not exceed 60 g/week
Serious - Use Alternative
Significant - Monitor Closely
Worsening psoriasis (3.4%)
Skin atrophy (1.9%)
Burning sensation (1.4%)
Skin depigmentation (1.4%)
Hand dermatitis (1%)
Known or suspected disorders of calcium metabolism
Erythrodermic, exfoliative, and/or pustular psoriasis
Hypercalcemia observed with use of calcipotriene
Discontinue if irritation develops
Do not apply to on face, axillae, or groin
Do not apply to areas of pre-existing skin atrophy
If concomitant skin infection present/develops, apply appropriate antifungal or antibacterial agent
Systemic absorption of topical corticosteroids
- Avoid application over large surface areas, prolonged use, and occlusive dressings that may increase risk for corticosteroid adverse effects
- Pediatric patients are at a greater risk than adults of systemic toxicity when treated with topical drugs and at greater risk of HPA axis suppression and adrenal insufficiency upon topical corticosteroid use
- Excessive systemic absorption may cause HPA axis suppression, Cushing syndrome, hyperglycemia, glucosuria
Pregnancy & Lactation
Pregnancy Category: C
Lactation: unknown whether distributed in breast milk, safety during breast feeding not established
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Calcipotriene: In vitro evidence suggests drug is roughly equipotent to natural vitamin D in its effects on proliferation & differentiation of various cell types
Betamethasone: Corticosteroid; elicits anti-inflammatory, antipruritic, and vasoconstrictive properties
Do not apply to face, axillae, or groin, or if skin atrophy is present at treatment site
Wash hands after application
- Rub ointment into skin gently and completely
- Do not treat >30% of body surface area
- Shake bottle prior to use
- Do not use with occlusive dressings unless directed by a physician
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.